# Hers Health, Inc. Reports Third Quarter 2026 Financial Results

> **Open Intelligence Dossier** · First detected: 2026-11-09 21:40 UTC · Category: Business

## Executive Summary
Hims & Hers Health reported Q3 2026 revenue of $401.6 million, up 69% year over year, but narrowed its full-year revenue guidance and cut its adjusted EBITDA forecast, sending shares down sharply.

## Intelligence Brief
Hims &amp; Hers Health (NYSE: HIMS) announced third-quarter 2026 results after the market closed on November 9, 2026. The company reported revenue of $401.6 million, a 69% increase from the same quarter a year earlier, and total subscribers of 2.2 million, up 54% year over year, according to the company&#039;s investor relations release and Reuters. Net loss widened to $14.9 million, or $0.07 per share, compared with a net loss of $3.2 million, or $0.02 per share, in Q3 2025. Adjusted EBITDA was $33.1 million, representing an 8.2% margin, down from $24.5 million and a 10.3% margin a year earlier.


The company narrowed its full-year 2026 revenue guidance to $1.53 billion to $1.55 billion, down from a prior range of $1.54 billion to $1.58 billion, and lowered its adjusted EBITDA outlook to $130 million to $135 million from $140 million to $150 million previously. The Wall Street Journal reported that the midpoint of the new revenue range implies about 55% growth for the year, while the adjusted EBITDA midpoint suggests a margin near 8.7%, below the roughly 9.5% margin implied by the prior guide. Reuters said the company cited higher marketing spend, increased costs from its GLP-1 weight-loss offerings, and continued investment in international expansion and AI tools as reasons for the margin pressure.


Shares fell about 15% in after-hours trading following the release, according to Yahoo Finance and Investor&#039;s Business Daily. Quiver Quantitative noted the stock was down 7.3% during the regular session ahead of the report, as investors weighed the recent expansion of access to Eli Lilly&#039;s branded obesity medicines Zepbound and Foundayo through the Hims &amp; Hers platform. The company said the agreement allows eligible patients to access those medicines, but analysts have questioned whether the arrangement will compress margins or increase operating costs. Barron&#039;s and Benzinga highlighted that the market reaction reflects concern over the path to profitability amid rapid top-line growth. The company&#039;s next earnings release has not been dated in the provided materials.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Simply Wall St | How Investors Are Reacting To SELLAS Life Sciences Group Stock As Final Trial Analysis Begins | [Source Link](https://news.google.com/rss/articles/CBMi8AFBVV95cUxNem9fQjVkdENwVElQdUYwZVhIRFExZkVha2VPdHFmVGdQUkRTeWxkU3lYcFNJai1XMS1vcld4UmFmY2lLMGtzWTd6blc2b3RHWWRRWWlodmxLXzl6dWJZZFVSR3NOdmo4UXg0aGwyX0d4VnNQY0JCU0JHb0hvS2xBbUFHYWFQdEpPZ3VUR29YV0ctVXRqaTd4RTZ3Z3AyakZYRnhrclhSMVVDTk9MVXF4SW9XbV9FS2t4OFNuVkJNU0tzRmpvQ2c0b2o2a2RyNXYxYkNmR1FMelB2N0RTWGZmOG56Wk1McXcta0JIY3M2bjfSAfYBQVVfeXFMUG13UnZmVHpZQzUtX2tjX3VxanFjZjFIaU40YkxxS3FpMzVVeDhNeExSYmpod3IwazJxV0M4bmUxamYzT0xtYmxYLUZ1VUpFTUI3VHRyWHVZMHZXNTVfSUNWTDU) |
| TradingView | Sellas Life Sciences shares jump as key leukemia trial results near | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxNMTJwYjh2YXU4NkhYMVVLcUZlZjBNUlZFZW5mVHRxd2lBNFZrMldVQnhubFFXeldhem5pc3RlZFBIZFMtUUE1OG1OU1BsMmZKclhYa0RoUHJfOXFrbXhGampObHNxNkViblBkTE9SSzFEejJ3SHc2LUE2a0FYU29mVGJQWHRQeVo0YWdoclpadlVheEZsNGR1d29PT3VMclF3SVJPbXhvQTRmdkxhX01ucWdmSlpPejdlWDBKRFRkYnJGMWo3eGE1TWhn?oc=5) |
| GuruFocus | SLS SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing | [Source Link](https://news.google.com/rss/articles/CBMivgFBVV95cUxQMTlYN3I3Q3hWemhFM2FmU1g3YVU2U0hUSk0tUm80VlBuTlBWQlVtYklfc1FCeGs0UkJTMFZWR0laOEFHYnNQbmJ5SzB2NFRPWEZ4b1RDdS01WnEtNUxaV2JBZERNeW0zdG9XQlFQckJ0SXgtTHYwT05ralFHVmd0ZVZMeGF3MmZoMWRtcEVOMnN6b1FiRjl3U1NUZzdEYk10MFliSmpuMVNEVnllWllyVXdmeGk4WVE0V1ZCMTNR?oc=5) |
| CancerNetwork | Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxPV3FZNXBobHVtdmxGUmE3V0twVHpJZkZHMlRKZGU1RnE4dHUzbHpFeGhFeGh6VWVod1p1cWZ2WnV5Mi1IN3JOam9SMnB0Q0ZkTEMxX0huWHRYczdwR2NESGFLQWhGaDRGTGFiN2M1OUg2SVNHX3U1QjlVczNtTUlWV0hxS01PblZEOU5XZnVoQlVmSVI5OXJMU3VvdGFGcURJa0w1cFQ3bDE5NDAyM1p3?oc=5) |
| Sellas Life Sciences | SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update | [Source Link](https://news.google.com/rss/articles/CBMi-AFBVV95cUxQRUtQbkN3TmRQd2dTME1obnZPcHlkZG9vLXQ3ME9VRFp3OFZzaE9uYndHWF93UjJ0MlVETkY2aHUzY05KUVBfUTYzQUEwNDVSbnV6SzQ0ellwb1BrQnlwM3BMbENaWTdBUzI1WXRfck9nVThhV3FYVmNwNkN3WFN6Q2tTdTlLdGZOU2xKX29WMmEtcGhxTzJoMzVQaXpjaFU2bEtpY1pFYzhOdXN5ZElUX2JMUXdjZ1ZhZG05YmFMa1hqZGU2amU4WnJqWG10OFk2ZEx1MGFvYlZ3S1JEMHZBc1JSZklXcEZnX1Vtd3ZUQ2dDUmZSbEdKNw?oc=5) |
| qz.com | Hims & Hers posted a surprise Q3 2026 earnings loss and cut its forecast | [Source Link](https://news.google.com/rss/articles/CBMidEFVX3lxTE1KWHdhTkd4cWYxeEczYTZOaldRY1ktWkt5VVNMbWtTQ1RTd2RPYVRpWjdXb1dGVWhldVR0OTMyRTltZUs5TGtZZzY0czZGYXc3bWk1RnFaU2dWNGthTzgzbWRhUVh1QXJ6OGFjblRJc3Bvczdp?oc=5) |
| Yahoo Finance | What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxPWERkU0d5bmhGMTBWOEp4bDBfZGpfSkNqM3ZPYVZwaWIyRnVoSDE2b2FBQzYtMjRYOUxKYnZmWkRmRmpCd0laVkhRcjh6LTQxUGpUQWVjb0JlYjZqNnVWSHBtR1QyN21UVXBENkJFUlBoSU45c0tqMkxkZXlyZWJhbjlmVVpMVlhaNmFzbFh0aEk?oc=5) |
| Yahoo Finance | HIMS Stock Tumbles After-Hours On Surprise Q3 Loss And Cut Profit Outlook: Retail Demands Answers | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxPU0RCZnB0aFhPM0V4eDMwVkxaeUhCYTloMkZxQVNuSWNKYVlmWHR6b0taSHFIZnRsVG9yVWZmY2N5VndFaXpBaEhKY3dBazR3REdiUDdWWUp0T1B1RDNrbjJvN0VFUlBmckdaVERaOWZsZm9UeEdJN3lzNWUyWWpuQ2dtZzNTYzB4V0IyemJxZURlMU82S2d2Z05n?oc=5) |
| Yahoo Finance | Hims & Hers Health (HIMS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxOS0lreGxFZVNuUVpZaHNfSkxSYVJBQ2d0MVdUZXlrSTIyUVozczhOTzhOVTV5QWhBXzZ5TmpnSTJDSjk0aTROYWpBTlJucFBVOEp1cjBnb3czRkt6MmlBNU1ON2tqZnJlYzBVOXRQb2NQS3o5S1loY0NIOC1HTTRzNTNJTmpjd0liVFlLNVB3?oc=5) |
| Yahoo Finance | Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxNRjJwcC02cDR5STk2WEYzdU42YmRJNXQyYWhJYVVJSmlMOUNacXdfNVpwMWYzNlFobjZpaDlnenNvVndvcGFTYXVTVGdjSlptN3dNSFhqR2xqQVhTVUYxbTRXb2dHY3N3ajlqdjk3Q0Q2ZEZRLWRnbUlVODdpcmVHbGJzeXFXXzEwZVdGaTdkem8?oc=5) |
| TradingView | Hims & Hers Health earnings: what to look for from HIMS | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxOMklOdVVhUVZSZXdvdjhYLTlIWU5BYVlVTFZjOTlLZWRneTV2bjNJd0l6Mms4d29Fc2d2ZXkxQ05heUxRUl9Ic3ZTeFY3TUotb1c1akJVUFlDOGZPNWxNbk0xcjRDWnY1UHhsV1RsLUE1R3N6Z0Y2Y1ZaTV9VeG9ZdUd1anNBRHpCRWt1REZaU0cxaW1XdEJHb3NIZTItUVd6YTgzeF9jbDJHYURPc2JJOGpJZw?oc=5) |
| WSJ | Hims & Hers Narrows Sales Outlook | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxQSkhKT1Rid3RrckI0cE9PaGl1cU5JWmR3UDFmQzktWXFMZG84VkxfMUZJOGhCQUlkMVpSeXh6MmZhaVNtU1VlcnhxT05fNllRV3ZNS0c3VFUtRVhoZnNraHp5SGVsQkNpMWg2M0NNZkFaS2RFOHBEYmNMckVzVWxkQ0pkeDQ?oc=5) |
| Reuters | Hims & Hers cuts 2026 profit forecast as margins contract | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxQbW9FTGJGOUVRZXB0SHN3WHdBS3JnOExrSlB1OU5rWVJDT252OTNfTnlVdkdiQzJieG9IZFJmZnVfeVFsbU82LVNNVlI3QkhjMzNyYXZzUWtCSEpvOVJfOTFBZUdWRmRqYkRmSFlPUVRxRVhhQWpfbDQ2emZNRzhaVEpFX1EzeEpxY2llUkNWWnhZTWc3dWw0ZWJRZk4zbnZ4WlpQN0s4WFU2YzhxMXE3bVp5cFNRMThfWE9HQ3JydmlfRnJlLVhN?oc=5) |
| Benzinga | Hims & Hers Stock Plunges Before Earnings: What to Watch | [Source Link](https://news.google.com/rss/articles/CBMiugFBVV95cUxQS3haclJlcHVIZ3pOMDFGR3Y0bWkyMzRmQmFmOHNaRUQ1OGNRSnFMWW5iTDZzc3Q2dmlSeXNrM1pKS3V0Ql90Wmo4d05SUW53RDRoaEhhWGlDLXJaQVgxR25EVDZTNm42TGJCRV96VVBQVmh5M3YtbUFiSUpEY3BVa096YWJjT3lueDVKNjZzNnIwRzYxMnRBRk1vcVZMZTZoNFBTY25vUV83OWQ0Z2NKNkhGZGlPOEdHblE?oc=5) |
| Quiver Quantitative | Hims & Hers Health Shares Fall as Investors Weigh Recent GLP-1 Expansion and Upcoming Earnings | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxNY2dZS3VXOVJZeFlvU1dkMFZhbVgtYmZqNHdSY29zWWo1SGFmeU9yd0FFTllmM0MwQkYtMDNGSnhiWjQ4bmlJRlNlRjZUSFJrR2RpOW13ZkZhRDZ5TFhPZ2R5VzM5cGZTMUJ5YnhCeVkzRmdZQTI3RWFacE5PcmV0Q0JVSzhROERnVFFrLVlnQmlNTUhMdVJfU0VuWWY0RW1wNWJKaTAtNTdrRkhMWm90X0pob0xWaTI4UGhDWXFoM19WTzEwVlEwcg?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-09/hers-health-inc-reports-third-quarter-2026-financial-results*
